New Jersey • Lyme Disease • Vaccines
Lyme Disease Vaccines: Where Things Stand in 2026
The short answer first: there is no Lyme disease vaccine you can get today. But that answer is closer to changing than it has been in over twenty years. In March 2026, Pfizer and Valneva announced encouraging Phase 3 results for their Lyme vaccine candidate, and Moderna has an mRNA-based candidate in early human trials. Here is an honest look at where each effort stands, what happened the last time a Lyme vaccine reached the market, and what it all means for New Jersey families right now.
The Weekly Bite
Get 5 fresh yard-defense reads every Wednesday
Tick and mosquito intel for North Jersey yards. No spam, unsubscribe anytime.
Quick Guide: the 60-second version
- No Lyme disease vaccine is available to the public right now. Anyone telling you otherwise is mistaken.
- The frontrunner is Pfizer and Valneva’s VLA15 (now called PF-07307405), which showed about 73% efficacy in a Phase 3 trial announced March 2026. Regulatory filings are planned, with possible availability in 2027 pending approval.
- Moderna’s mRNA Lyme vaccine (mRNA-1982) entered Phase 2 testing in April 2026 with about 350 adults in Canada. It is years behind the frontrunner.
- The only Lyme vaccine ever approved in the US, LYMErix, was withdrawn in 2002 amid controversy and weak sales.
- Until a vaccine exists, prevention is still the whole game: tick checks, repellents, prompt removal, and treating your yard.
The Bottom Line Today
As of September 2026, no Lyme disease vaccine is approved or available anywhere in the world. The candidates in development are real and the latest results are genuinely encouraging, but a vaccine in a Phase 3 trial is not a vaccine at your pharmacy. It still has to clear regulatory review, manufacturing scale-up, and distribution, and any of those steps can slow things down or change the outcome.
What Happened to LYMErix
This is not the first time we have been here. In 1998, the FDA approved LYMErix, a Lyme disease vaccine made by SmithKline Beecham. It was the only Lyme vaccine ever brought to market in the United States. Within a few years, reports of arthritis and other side effects, which later investigations did not substantiate, combined with weak public demand and lawsuits, and the manufacturer pulled it in 2002.
The LYMErix story matters because it explains why the current developers are being so careful, and why public trust will be as important as the science if a new vaccine reaches the market. A vaccine that works but that nobody trusts is a vaccine that fails.
Pfizer and Valneva: The Frontrunner
The most advanced candidate is VLA15, now called PF-07307405 (or LB6V), developed by the French biotech Valneva with Pfizer. It is a traditional protein-based vaccine targeting OspA, a protein on the surface of the Lyme bacterium, and it covers six strains of the bacteria found in North America and Europe.
On March 23, 2026, the companies announced topline results from the Phase 3 VALOR trial, which enrolled about 9,400 participants aged 5 and older across the US, Canada, and Europe:
- Efficacy of 73.2% in reducing confirmed Lyme disease cases compared to placebo, measured from 28 days after the fourth dose.
- Efficacy of 74.8% measured from one day after the fourth dose.
- The trial missed its primary statistical endpoint in the first prespecified analysis, because fewer Lyme cases occurred during the study than expected, but met the efficacy threshold in a second prespecified analysis.
- No safety concerns were identified.
Pfizer has said it is planning submissions to regulatory authorities. Industry reporting at the time pointed to a possible launch in the US and Europe in the second half of 2027, pending approval. Treat that date as an estimate, not a promise: it depends on regulators agreeing the data is strong enough.
Moderna’s mRNA Candidates: Earlier, But Worth Watching
Moderna is pursuing a different technical path with mRNA-based Lyme vaccines. Its candidate mRNA-1982 entered a Phase 2 trial in April 2026, enrolling about 350 healthy adults at sites in Canada to test safety and immune response, with results not expected until around 2028. An earlier, broader candidate, mRNA-1975, completed a Phase 1/2 trial of about 800 adults in May 2025.
The mRNA approach is attractive because the platform can be adapted quickly and could eventually cover multiple tick-borne diseases in one shot. But it is years behind the Pfizer/Valneva candidate. Do not expect an mRNA Lyme vaccine on the market this decade unless development accelerates dramatically.
How These Vaccines Actually Work
The Pfizer/Valneva vaccine works in an unusual way. Rather than training your body to fight the bacteria directly, it prompts your immune system to make antibodies against OspA, a protein the Lyme bacterium wears while living in the tick’s gut. When a tick bites a vaccinated person, it swallows those antibodies along with the blood meal, and the antibodies neutralize the bacteria inside the tick before they can be transmitted. It is a transmission-blocking vaccine: it fights the disease inside the tick, not inside you.
What This Means for Your Family Right Now
Honestly? Not much changes for the 2026 and 2027 tick seasons. Even in the best case, a vaccine would not be widely available before late 2027, and early supply would likely go to the highest-risk groups first. The CDC’s core prevention advice stands: use a plant-based repellent, do full-body tick checks, shower within two hours of coming inside, remove attached ticks promptly with fine-tipped tweezers, and keep the tick habitat in your yard under control.
A vaccine, when it arrives, would be one more layer of protection, not a replacement for those habits. No vaccine is 100% effective, and ticks in New Jersey carry more than just Lyme disease.
Laurie’s field note: I will believe in a Lyme vaccine when I can drive a customer to the pharmacy to get one. Until then, the families I protect rely on the unglamorous stuff: a treated yard, a tick check after the ballgame, tweezers in the bathroom drawer. That is what keeps people safe this season and next.
FAQ: Lyme Disease Vaccines
Is there a Lyme disease vaccine available now?
No. As of September 2026, no Lyme disease vaccine is approved or available to the public. The leading candidate is in late-stage trials with regulatory filings planned, but it has not been approved.
When might a Lyme vaccine be available?
The companies behind the frontrunner candidate have pointed to a possible launch in the second half of 2027, pending regulatory approval. That is an estimate, not a guarantee. Regulators could ask for more data, which would push the timeline back.
Why was the old LYMErix vaccine taken off the market?
LYMErix was approved in 1998 and withdrawn by its manufacturer in 2002. Reports of side effects that later studies did not confirm, combined with low public demand and lawsuits, made it commercially unviable. It was a business and trust failure as much as a scientific one.
How effective was the new vaccine in trials?
In the Phase 3 VALOR trial, the Pfizer/Valneva candidate showed about 73 to 75% efficacy in reducing confirmed Lyme disease cases versus placebo. The trial missed its primary statistical endpoint in the first analysis because fewer cases occurred than expected, but cleared the efficacy bar in a second prespecified analysis.
What is the mRNA Lyme vaccine, and how is it different?
Moderna’s mRNA-1982 uses messenger RNA to instruct your cells to make a Lyme bacterial protein, prompting an immune response. It is a different technology from the protein-based Pfizer/Valneva shot, and it is much earlier in testing, currently in Phase 2 with results expected around 2028.
Will a Lyme vaccine replace tick checks and repellents?
No. Even the best trial results showed around 73% efficacy, not 100%, and ticks carry other diseases besides Lyme. A vaccine would add a layer of protection on top of the standard precautions, not replace them.
Will children be able to get the Lyme vaccine?
The Phase 3 trial enrolled participants aged 5 and older, so children are included in the data regulators will review. Final age recommendations would be set by regulators and the CDC if the vaccine is approved.
Is there a Lyme vaccine for dogs?
Yes, and there has been for years. Several Lyme vaccines for dogs are on the market and widely used by veterinarians. The gap is only in human vaccines. Ask your veterinarian whether Lyme vaccination makes sense for your dog in New Jersey.
What should my family do about Lyme disease in the meantime?
The same things that have always worked: a plant-based repellent, protective clothing in tick habitat, full-body tick checks after being outdoors, prompt tick removal with fine-tipped tweezers, and reducing tick habitat in your yard. Talk to your doctor if you find an attached tick or develop symptoms.
The Takeaway: Real Progress, Not a Finished Story
For the first time in over two decades, a Lyme disease vaccine is genuinely close, with Phase 3 data in hand and regulatory filings on the horizon. That is real progress worth watching. But close is not here, and your family’s protection for the next few tick seasons still comes down to the basics: check for ticks, remove them quickly, and keep your yard from being a tick nursery.
Trusted sources: CDC: Lyme Disease • Pfizer/Valneva Phase 3 VALOR topline results (March 2026) • VALOR trial record (NCT05477524) • Moderna mRNA-1982 Phase 2 record (NCT07561294)
The Weekly Bite
Get 5 fresh yard-defense reads every Wednesday
Tick and mosquito intel for North Jersey yards. No spam, unsubscribe anytime.